Update shared on30 Aug 2025
Fair value Increased 1.07%Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum.
Analyst Commentary
- Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.
- Multiple upcoming pipeline catalysts, including three anticipated Phase 3 data readouts in 9 months (notably BBP-418 in LGMD2I/R9 and encaleret in hypocalcemia), are cited as key value drivers.
- Early launch momentum for Attruby in transthyretin amyloid cardiomyopathy (ATTR-CM) and potential blockbuster sales estimates are driving increased price targets, aided by positive physician feedback regarding differentiation versus Pfizer’s tafamidis.
- Pipeline diversification and the expectation of two additional product launches by late 2026/early 2027 are seen as de-risking factors moving the story beyond a single-asset focus.
- Analysts are raising targets to reflect higher sales expectations, updated commercial metrics, and the potential for further upward estimate revisions as more data emerge.
What's in the News
- BridgeBio Pharma will present new data from the ATTRibute-CM study on acoramidis' effects, including reductions in cardiovascular mortality and improvements in NT-proBNP and disease stage, at the European Society of Cardiology Congress 2025.
- The company was dropped from multiple Russell indexes, including the Russell 2000 Value, Small Cap Comp Value, 3000E Value, 3000 Value, and 2500 Value benchmarks and indexes.
- Stockholders approved an amendment to limit certain officers' liability under Delaware law, effective upon filing.
Valuation Changes
Summary of Valuation Changes for BridgeBio Pharma
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $62.43 to $63.10.
- The Future P/E for BridgeBio Pharma remained effectively unchanged, moving only marginally from 51.28x to 51.78x.
- The Discount Rate for BridgeBio Pharma remained effectively unchanged, moving only marginally from 6.97% to 6.94%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.